| scholarly article | Q13442814 |
| P50 | author | James F. Gusella | Q1602688 |
| P2093 | author name string | Hua Li | |
| Anat O Stemmer-Rachamimov | |||
| Margaret R Wallace | |||
| Vijaya Ramesh | |||
| Marianne F James | |||
| Sangyeul Han | |||
| Roberta Beauchamp | |||
| Elizabeth Stivison | |||
| P433 | issue | 5 | |
| P304 | page(s) | 649-659 | |
| P577 | publication date | 2012-03-16 | |
| P1433 | published in | Molecular Cancer Research | Q2751014 |
| P1476 | title | Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types | |
| P478 | volume | 10 |
| Q53821957 | 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. |
| Q36359705 | A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers |
| Q35380714 | A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2 |
| Q30396975 | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas |
| Q40867510 | A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. |
| Q47208014 | Advances in meningioma genetics: novel therapeutic opportunities |
| Q55638662 | CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. |
| Q92446819 | Case-Based Review: meningioma |
| Q90117861 | Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma |
| Q52940698 | Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. |
| Q92637203 | Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis |
| Q26851291 | Cutting through the complexities of mTOR for the treatment of stroke |
| Q30389069 | Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma |
| Q89458203 | EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma |
| Q38746881 | Immortalization of human normal and NF1 neurofibroma Schwann cells |
| Q27853151 | Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. |
| Q26825296 | Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator |
| Q35218073 | Neurofibromatosis-related tumors: emerging biology and therapies |
| Q26749047 | Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR |
| Q36432388 | Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade |
| Q41548629 | Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro |
| Q30422022 | Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. |
| Q27853117 | Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. |
| Q42223215 | Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells |
| Q92862814 | Recent Advances in Meningioma Immunogenetics |
| Q36189820 | Role of Merlin/NF2 inactivation in tumor biology |
| Q38180808 | Schwannomas and their pathogenesis |
| Q27015640 | Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin |
| Q26795544 | Stem cell guidance through the mechanistic target of rapamycin |
| Q38607849 | Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders |
| Q34886859 | The mTOR signaling pathway as a treatment target for intracranial neoplasms |
| Q52361076 | The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders. |
| Q30357776 | Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis |
| Q43158408 | Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR. |
| Q55383186 | Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. |
| Q39173616 | Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macro |
| Q30415483 | mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma |
| Q30401833 | p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. |
Search more.